CC2022: Bone Marrow Aspirate Concentrate for the Treatment of Knee Osteoarthritis: A Systematic Review (July 2022)-Bone Marrow Aspirate Concentrate for the Treatment of Knee Osteoarthritis: A Systematic Review (July 2022)

Bone Marrow Aspirate Concentrate for the Treatment of Knee Osteoarthritis: A Systematic Review (July 2022)

Pdf Summary

Bone marrow aspirate concentrate (BMAC) has emerged as a therapeutic option for symptomatic knee osteoarthritis (OA). This systematic review evaluated the efficacy of isolated BMAC injection in the treatment of knee OA. Eight studies were included, comprising a total of 299 knees with a mean follow-up of 12.9 months. The results showed that BMAC injection was effective in improving pain and patient-reported outcomes (PROs) in patients with knee OA at short- to midterm follow-up. Of all PROs assessed in the studies, 34 of 36 (94.4%) demonstrated significant improvement from baseline to the latest follow-up. However, three comparative studies evaluating BMAC in relation to other therapeutic injections failed to demonstrate its clinical superiority. BMAC has not demonstrated clinical superiority in relation to other biologic therapies commonly used in the treatment of OA, including platelet-rich plasma and microfragmented adipose tissue, or in relation to placebo. The high cost of the BMAC injection in comparison with other treatment modalities may limit its utility despite its clinical benefit. It is important to note that while BMAC injection is effective in improving pain and PROs in patients with knee OA, the clinical significance of these improvements and the long-term effects of BMAC remain unclear. Further research is needed to determine the precise mechanism of action of BMAC and to compare its efficacy to other treatment options.

Keywords

Bone marrow aspirate concentrate

BMAC

therapeutic option

symptomatic knee osteoarthritis

systematic review

efficacy

isolated BMAC injection

treatment of knee OA

patient-reported outcomes

short- to midterm follow-up